IE
GYRE icon

Israel Englander’s Gyre Therapeutics GYRE Stock Holding History

Israel Englander’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,333
Closed -$587K – 4597
2020
Q2 		$587K Buy
+13,333
New +$626K ﹤0.01% 3308

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Israel Englander's GYRE Position: Q2 2026 in Review

Israel Englander opened a new position in Gyre Therapeutics (GYRE) in Q2 2026: 18,488 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #5454 among its holdings. This is a return to the name: Israel Englander previously reported a position in GYRE as recently as Q3 2025.

Israel Englander first reported a position in GYRE in Q2 2013 and has held it in 32 quarters since. The position peaked at $6.71M in Q2 2020. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Israel Englander held 18,488 shares of Gyre Therapeutics worth $122K as of Q2 2026.
  • Gyre Therapeutics was a new Israel Englander position in Q2 2026.
  • Gyre Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5454 holding.
  • Israel Englander first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 32 quarters since.
  • Israel Englander's Gyre Therapeutics position peaked at $6.71M in Q2 2020.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.